Papers
3
Total Citations
46
H-Index
3
About
Dev Amin is a rising surgical oncologist whose research is reshaping the treatment landscape for head and neck cancers, particularly oropharyngeal squamous cell carcinoma (OPSCC). His work centers on three critical areas: optimizing treatment selection between primary surgery and chemoradiation, understanding the surgical implications of neoadjuvant immunotherapy, and refining preoperative risk stratification. In a landmark 2023 study (24 citations), Amin addressed a critical evidence gap by comparing functional and survival outcomes between primary transoral robotic surgery (TORS) and chemoradiation for early-stage OPSCC, providing real-world data where randomized trials are lacking. His investigation into preoperative immune checkpoint inhibition (13 citations) was among the first to systematically evaluate complication rates following neoadjuvant immunotherapy in head and neck cancer surgery—a rapidly evolving frontier. Most recently, Amin demonstrated that the modified frailty index (mFI-5) can predict complications and survival in the TORS population (9 citations), offering a practical tool for personalized surgical decision-making. Through these contributions, Amin is advancing precision oncology by integrating frailty assessment, immunotherapy sequencing, and comparative effectiveness research into head and neck cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3